Archive
-
2023/03/02Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)
-
2023/03/01Allist Pharmaceuticals Annouced Today the Signing of a License Agreement with Abbisko Therapeutics for a New Generation of EGFR TKI, called ABK3376
-
2022/08/05Furmonertinib Published in Prestigious International Journal Once Again
-
2022/08/04Ivesa® won the "14th China Health Forum - Top 10 New Drugs (in China)”
-
2022/07/22Allist listed on “TOP 100 Hardcore Technology Enterprises in Shanghai in 2022"
-
2022/06/29Furmonertinib Approved for First-Line Treatment
-
2022/06/03Furmonertinib Once Again Published in The Lancet Respiratory Medicine
-
2022/05/27New Evidence: Furmonertinib First-Line Treatment for CNS Metastases Data Released at the ASCO Annual Meeting
-
2022/03/23Press Release: Furmonertinib Being a First-line Drug to Treat Patients Suffering from Advanced NSCLC, with Progression-free Survival (PFS) of 20.8 Months
-
2022/01/04A New Year Begins with Furmonertinib Added to China’s National Medical Insurance Catalog